Novel use of amine-borane compounds for the treatment of medical conditions associated with microorganisms. These novel amine-borane compounds are an answer to the massive search being conducted for novel antimicrobial agents to deal with the...

Interactive website established

Novel use of amine-borane compounds for the treatment of medical conditions associated with microorganisms. These novel amine-borane compounds are an answer to the massive search being conducted for novel antimicrobial agents to deal with the development of resistance to current medications and the growing number of immunocompromised hosts. In addition these amine-borane compounds have been demonstrated to be non-toxic at their active concentration range. Keywords: antibacterial

Novel treatment for diseases associated with pathogenic microorganisms

Categories	Antimicrobial, antifungal, antiparasitic, antimalarial
Development Stage	Interactive website established
Patent Status	U.S. patent application filed (PCT publication No. WO2007032004)
Market Size	2004 antibiotics market was worth nearly $24 billion: the annual cost of treating drug-resistant infections is more than $10 billion.

Highlights

• Novel use of amine-borane compounds against moulds, yeasts and higher fungi, as well as parasites and protozoa
• Effective against drug resistant organisms such as fluconazole/amphotericin B resistant Candida
• Effective treatment for harmless diseases and infections such as candidiasis (thrush) and athlete's foot which can prove fatal to immunocompromised patients

Our Innovation

• Amine-borane compounds, such as amine cyanoboranes and amine carboxyboranes, are isoelectronic and isostructural analogs of many biologically active compounds and mimic the biological activity of these compounds in the body

Key Features

• Novel use for amine-borane compounds previously used in poorly-understood anti-cancer, anti-hyperlipodemic, anti-inflammatory, and other applications
• Solution for drug resistant organisms including malaria and leishmaniasis parasites
• Non-toxic to humans at drugs active concentration range

Development Milestones

• Develop more potent analogs against fluconazole/amphotericin resistant Candida strains
• Exploring use of amine cyanoboranes as coatings for medical implants such as catheters and stents to prevent the occurrence of biofilms

The Opportunity

• 500 million people per year afflicted with parasites and protozoa such as malaria and leishmaniasis
• In the US alone, infections on indwelling medical devices - such as catheters, prosthetic joints, and mechanical heart valves - cost the health care system approximately $1 billion/year
• The global market for antimalarial drugs of the order of  $100-120 million per year

project-id 7-2006-324

Registered

U.S. patent application filed (PCT publication No. WO2007032004)